NSPR

$1.79

Post-MarketAs of Mar 17, 8:00 PM UTC

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific.

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$1.79
Potential Upside
5%
Whystock Fair Value$1.88
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryMedical Devices

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery and other vascular diseases in Europe, Latin America, the Middle East, and the Asia Pacific. The company offer...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$75.84M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-87.61%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
6.09

Recent News

Zacks
Mar 3, 2026

NeuroPace, Inc. (NPCE) Reports Q4 Loss, Beats Revenue Estimates

NeuroPace (NPCE) delivered earnings and revenue surprises of +41.48% and +2.47%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Jan 10, 2026

InspireMD (NASDAQ:NSPR) shareholders have endured a 81% loss from investing in the stock five years ago

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. It hits us in the gut...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Simply Wall St.
Nov 27, 2025

Is InspireMD (NASDAQ:NSPR) In A Good Position To Invest In Growth?

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Nov 4, 2025

InspireMD Inc (NSPR) Q3 2025 Earnings Call Highlights: Robust Revenue Growth Amid Rising Expenses

InspireMD Inc (NSPR) reports a 39% revenue increase driven by the US launch of CGuard Prime, despite a widened net loss and increased operating expenses.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Nov 4, 2025

InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates

InspireMD (NSPR) delivered earnings and revenue surprises of 0.00% and +31.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.